Enzon Pharmaceuticals, Inc.

ENZN

US2939041081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:46:29 2024-05-31 pm EDT			5-day change	1st Jan Change
0.13 ^USD	+18.18%		-10.34%	+38.89%

May. 10	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 20	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Enzon Pharmaceuticals Inc. Appoints George W. Hebard III as Director

February 28, 2012 at 05:24 pm EST

Enzon Pharmaceuticals Inc. appointed George W. Hebard III as a director to fill the newly-created vacancy. Since September 2011, Mr. Hebard has been a Managing Director at Icahn Capital LP.

Latest news about Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-04	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-23	CI
Enzon Pharmaceuticals, Inc. Announces Executive Changes	21-01-04	CI
Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary	21-01-04	CI
Declaration of Voting Results Enzon Pharmaceuticals	20-12-21	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Enzon Pharmaceuticals Solicits Proxies from the Shareholders	20-11-03	CI
Enzon Pharmaceuticals to Seek Acquisition Opportunities	20-10-21	CI
Enzon Pharmaceuticals, Inc. Provides Information to the Shareholders	20-08-10	CI
Enzon Pharmaceuticals, Inc. Announces Board Changes	20-08-07	CI
Jonathan Couchman Nominates Candidates to the Board of Enzon Pharmaceuticals	20-08-05	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-07-29	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-30	CI

Chart Enzon Pharmaceuticals, Inc.

Duration

Period

More charts

Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENZON PHARMACEUTICALS, INC.	+38.89%	9.65M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B